➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Dow
McKesson
Harvard Business School

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for VTP-194204


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug VTP-194204?

VTP-194204 is an investigational drug.

There have been 17 clinical trials for VTP-194204. The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Erectile Dysfunction. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.

There are seventeen US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for VTP-194204
TitleSponsorPhase
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate CancerSteba Biotech S.A.Phase 3
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate CancerInternational Drug Development InstitutePhase 4
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate CancerPrimeVigilance LTDPhase 4

See all VTP-194204 clinical trials

Clinical Trial Summary for VTP-194204

Top disease conditions for VTP-194204
Top clinical trial sponsors for VTP-194204

See all VTP-194204 clinical trials

US Patents for VTP-194204

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VTP-194204   Start Trial Autoimmune disorder treatment using RXR agonists lo Therapeutics, Inc. (Santa Ana, CA)   Start Trial
VTP-194204   Start Trial Treatment of cancer with specific RXR agonists Io Therapeutics, Inc. (Santa Ana, CA)   Start Trial
VTP-194204   Start Trial Treatment of cancer with specific RXR agonists IO Therapeutics, Inc. (Santa Ana, CA)   Start Trial
VTP-194204   Start Trial Autoimmune disorder treatment using RXR agonists IO Therapeutics, Inc. (Santa Ana, CA)   Start Trial
VTP-194204   Start Trial Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones IO Therapeutics, Inc. (Santa Ana, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VTP-194204

Drugname Country Document Number Estimated Expiration Related US Patent
VTP-194204 Australia 2012352149 2031-12-13   Start Trial
VTP-194204 Australia 2017210644 2031-12-13   Start Trial
VTP-194204 Canada 2858882 2031-12-13   Start Trial
VTP-194204 China 104114171 2031-12-13   Start Trial
VTP-194204 China 110151745 2031-12-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Colorcon
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.